EcoDrugPlus

Integrin, Beta 1b

Ensembl ID : ENSGACG00000001584
Gene Symbol: ITGB1B
1 Cross references
230 Possible Orthologues:

Integrin, Beta 5

Ensembl ID : ENSGACG00000008632
Gene Symbol: ITGB5
1 Cross references
211 Possible Orthologues:

Interleukin-1 Receptor-Associated Kinase 4

Ensembl ID : ENSGACG00000004050
Gene Symbol: IRAK4
1 Cross references
202 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSGACG00000009167
Gene Symbol: IDH1
1 Cross references
234 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSGACG00000016476
Gene Symbol: IDH2
1 Cross references
204 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSGACG00000010827
Gene Symbol: IDH2
1 Cross references
196 Possible Orthologues:

Kelch-Like Ech-Associated Protein 1b

Ensembl ID : ENSGACG00000019479
Gene Symbol: KEAP1B
1 Cross references
189 Possible Orthologues:

Kinase Insert Domain Receptor (A Type Iii Receptor Tyrosine Kinase)

Ensembl ID : ENSGACG00000014277
Gene Symbol: KDR
1 Cross references
198 Possible Orthologues:

Kinesin Family Member 11

Ensembl ID : ENSGACG00000011110
Gene Symbol: KIF11
1 Cross references
202 Possible Orthologues:

Kinesin Family Member 5b

Ensembl ID : ENSGACG00000017607
Gene Symbol: KIF5B
2 Cross references
245 Possible Orthologues:

Kinesin Family Member 5b

Ensembl ID : ENSGACG00000001018
Gene Symbol: KIF5B
2 Cross references
243 Possible Orthologues:

Lectin, Galactoside Binding Soluble 3a

Ensembl ID : ENSGACG00000011778
Gene Symbol: LGALS3A
1 Cross references
219 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).